Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Breast Cancer and Chemo-amennorhea (chemo-ameno)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01867229
Recruitment Status : Completed
First Posted : June 3, 2013
Last Update Posted : April 10, 2019
Sponsor:
Information provided by (Responsible Party):
Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Relation between chemotherapy and amennorhea

Condition or disease Intervention/treatment
Breast Cancer Other: observational

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Actual Enrollment : 7 participants
Observational Model: Other
Time Perspective: Prospective
Official Title: Etude Prospective Multicentrique de l'aménorrhée Chimio-induite et de sa réversibilité Dans le Cancer du Sein Chez Des Patientes préménopausées Recevant Une chimiothérapie Adjuvante ou néoadjuvante. Etude Améno-Chimio.
Study Start Date : October 2011
Actual Primary Completion Date : December 2013
Actual Study Completion Date : December 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
FEC- TC
Fluorouracil- Epiadriamycine- Cyclophosphamide Taxotère-Cyclophosphamide
 Other: observational
standard of care fore patients with non metastatic breast cancer


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. incidence and duration of the amenorrhea induced by chemotherapy [ Time Frame: 5 years ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
pre-menauposal breast cancer treated with chemotherapy
Criteria

Inclusion Criteria:

pre-menauposal breast cancer needed to be treat with chemotherapy -

Exclusion Criteria:

metastases menopausal

-

Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01867229


Locations
Layout table for location information
Belgium
Clinique Saint Vincent
Rocourt, Liège, Belgium, 4000
Cliniques Universitaires Saint-Luc
Brussels, Belgium, 1200
Centre Hospitalier Université de Liège
Liège, Belgium, 4000
CHR Citadelle
Liège, Belgium, 4000
Centre hospitalier Peltzer La Tourelle
Verviers, Belgium, 4800
France
Institut Claudius Renaud
Toulouse, France, 31059
Sponsors and Collaborators
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Investigators
Layout table for investigator information
Principal Investigator: jean-Pascal Machiels UCL-Saint Luc
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
ClinicalTrials.gov Identifier: NCT01867229    
Other Study ID Numbers: UCL-gyneco-001
2009/07DEC/377 ( Other Identifier: CEHF )
First Posted: June 3, 2013    Key Record Dates
Last Update Posted: April 10, 2019
Last Verified: April 2019
Keywords provided by Cliniques universitaires Saint-Luc- Université Catholique de Louvain:
pre-menauposal
neo-adjuvant or adjuvant chemotherapy
no metastases
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases